New clinical data and partnership details unveiled at ISICEM 2026.
- CytoSorbents introduces HotSwap technology.
- Renewed partnership with Aferetica announced.
- New clinical data presented at ISICEM 2026.
CytoSorbents has launched its new HotSwap technology and announced a renewed partnership with Aferetica, as highlighted at the ISICEM 2026 conference. This innovative product aims to enhance patient care in critical situations. The CytoSorbents HotSwap technology is designed to streamline the process of removing cytokines from the bloodstream, potentially improving outcomes for patients with severe inflammation.
During the conference, the company also presented new clinical evidence supporting the effectiveness of their products in therapeutic applications. The collaboration with Aferetica is expected to facilitate advancements in blood purification technologies and improve patient support. This partnership builds on previous efforts to innovate within the medical field and underscores the commitment of both entities to enhancing patient care.
The engagement at ISICEM 2026 provided a venue for CytoSorbents to share insights and findings with healthcare professionals. These developments highlight the ongoing research efforts and clinical trials that aim to build upon established techniques in critical care. Overall, the advancements showcased signify a step forward in addressing complex medical challenges.
